Literature DB >> 18998719

Influence of the molecular charge on the biodistribution of bombesin analogues labeled with the [99mTc(CO)3]-core.

Elisa García Garayoa1, Christian Schweinsberg, Veronique Maes, Luc Brans, Peter Bläuenstein, Dirk A Tourwe, R Schibli, P August Schubiger.   

Abstract

The overexpression of Bombesin (BBS) receptors on a variety of human cancers make them interesting targets for tumor imaging and therapy. Analogues of the neuropeptide BBS have been functionalized with the (NalphaHis)- chelator for labeling with the 99mTc-tricarbonyl core. The introduction of a betaAla-betaAla linker between the stabilized BBS binding sequence and the chelator led to increased tumor uptake but still rather unfavorable in ViVo properties. Novel polar linkers, with different charge, have been introduced in the molecule and tested for their influence on the biodistribution. The new analogues showed a shift in hydrophilicity from a Log D=0.9 to Log D values between 0.4 and -2.2. All compounds kept the increased stability in both human plasma (t(1/2)>16 h) and in tumor cells (t(1/2)=30-40 min). The compounds with Log D values between +1 and -1 showed the highest binding affinities with Kd values of <0.5 nM, as well as the highest cellular uptake. However, higher hydrophilicity (Log D < -1.8) led to lower affinity and a substantial decrease of internalization. The introduction of a positive charge (beta3hLys) resulted in unfavorable biodistribution, with increased kidney uptake. The introduction of an uncharged hydroxyl group (beta3hSer) improved the biodistribution, resulting in significantly better tumor-to-tissue ratios. The compound with one single negative charge (beta3hGlu) showed a significant increase in the tumor uptake (2.1+/-0.6% vs 0.80+/-0.35% ID/g in comparison to the betaAla-betaAla analogue) and also significantly higher tumor-to-tissue ratios. The specificity of the in ViVo uptake was confirmed by coinjection with natural BBS. Moreover, the analogue provided a much clearer image of the tumor xenografts in the SPECT/CT studies. The introduction of a single negative charge may be useful in the development of new BBS analogues to obtain an improved biodistribution profile, with increased tumor uptake and better imaging.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18998719     DOI: 10.1021/bc800262m

Source DB:  PubMed          Journal:  Bioconjug Chem        ISSN: 1043-1802            Impact factor:   4.774


  25 in total

1.  Designed hydrophilic and charge mutations of the fibronectin domain: towards tailored protein biodistribution.

Authors:  Benjamin J Hackel; Ataya Sathirachinda; Sanjiv S Gambhir
Journal:  Protein Eng Des Sel       Date:  2012-06-12       Impact factor: 1.650

2.  Synthetic and natural consensus design for engineering charge within an affibody targeting epidermal growth factor receptor.

Authors:  Brett A Case; Benjamin J Hackel
Journal:  Biotechnol Bioeng       Date:  2016-02-04       Impact factor: 4.530

Review 3.  Bombesin receptor-mediated imaging and cytotoxicity: review and current status.

Authors:  Veronica Sancho; Alessia Di Florio; Terry W Moody; Robert T Jensen
Journal:  Curr Drug Deliv       Date:  2011-01       Impact factor: 2.565

Review 4.  Radiopharmaceutical development of radiolabelled peptides.

Authors:  Melpomeni Fani; Helmut R Maecke
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-02       Impact factor: 9.236

5.  Use of (64)Cu-labeled fibronectin domain with EGFR-overexpressing tumor xenograft: molecular imaging.

Authors:  Benjamin J Hackel; Richard H Kimura; Sanjiv S Gambhir
Journal:  Radiology       Date:  2012-02-17       Impact factor: 11.105

6.  Engineered Charge Redistribution of Gp2 Proteins through Guided Diversity for Improved PET Imaging of Epidermal Growth Factor Receptor.

Authors:  Brett A Case; Max A Kruziki; Sadie M Johnson; Benjamin J Hackel
Journal:  Bioconjug Chem       Date:  2018-04-05       Impact factor: 4.774

7.  Introduction of an 8-aminooctanoic acid linker enhances uptake of 99mTc-labeled lactam bridge-cyclized α-MSH peptide in melanoma.

Authors:  Haixun Guo; Yubin Miao
Journal:  J Nucl Med       Date:  2014-11-07       Impact factor: 10.057

8.  Effects of the amino acid linkers on the melanoma-targeting and pharmacokinetic properties of 111In-labeled lactam bridge-cyclized alpha-MSH peptides.

Authors:  Haixun Guo; Jianquan Yang; Fabio Gallazzi; Yubin Miao
Journal:  J Nucl Med       Date:  2011-03-18       Impact factor: 10.057

9.  Optimization of a Pretargeted Strategy for the PET Imaging of Colorectal Carcinoma via the Modulation of Radioligand Pharmacokinetics.

Authors:  Brian M Zeglis; Christian Brand; Dalya Abdel-Atti; Kathryn E Carnazza; Brendon E Cook; Sean Carlin; Thomas Reiner; Jason S Lewis
Journal:  Mol Pharm       Date:  2015-08-31       Impact factor: 4.939

10.  Effects of chelator modifications on (68)Ga-labeled [Tyr (3)]octreotide conjugates.

Authors:  Mai Lin; Michael J Welch; Suzanne E Lapi
Journal:  Mol Imaging Biol       Date:  2013-10       Impact factor: 3.488

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.